IMR-1
Based on 6 publication(s) in Google Scholar
IMR-1 is a novel class of Notch inhibitor targeting the transcriptional activation with an IC50 of 26 μM. IMR-1 prevents the recruitment of Mastermind-like 1 (Maml1) to the Notch Ternary Complex (NTC) on chromatin, inhibits Notch target gene transcription and dramatically inhibits tumor growth.
For research use only. We do not sell to patients.
- Purity: 98.95%
- CAS No.: 310456-65-6
- Formula: C15H15NO5S2
- Molecular Weight:353.41
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Neuronal Signaling Compound Library
HY-L013
-
Stem Cell Signaling Compound Library
HY-L017
-
Wnt/Hedgehog/Notch Compound Library
HY-L020
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Covalent Screening Library
HY-L036
-
Differentiation Inducing Compound Library
HY-L038
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Angiogenesis-Related Compound Library
HY-L088
-
Transcription Factor-Targeted Library
HY-L090
-
Anti-Liver Cancer Compound Library
HY-L101
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
Cancer Stem Cells Compound Library
HY-L135
-
Heterocyclic Compound Library
HY-L138
-
Bioactive Compound Library Max
HY-L181
-
Covalent Screening Library Plus
HY-L036P
-
Bioactive Compound Library
HY-L001
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
-
Anti-Rheumatic Arthritis Compound Library
HY-L210
Publications Citing Use of MedChemExpress (MCE) IMR-1
More- J Nanobiotechnology. 2026 Mar 6;24(1):345. [Abstract]
- Int J Biol Sci. 2020 Jan 1;16(4):598-610. [Abstract]
- Oncogene. 2023 Aug;42(34):2521-2535. [Abstract]
- Cell Chem Biol. 2022 Aug 18;29(8):1260-1272.e8. [Abstract]
- JCI Insight. 2022 Dec 8;7(23):e162402. [Abstract]
- Tissue Cell. 2024 Dec:91:102554. [Abstract]
Customer Validation & Images
-
Cell Proliferation/Viability Assay
Biological Activity
IC50: 26 μM (Notch)[1]
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Nude mouses with adenocarcinoma xenograft[1]
-
Dosage:15mg/kg
-
Administration:I.p.; for 28 days
-
Result:Blocks tumor establishment.
Chemical Information
-
CAS No. 310456-65-6
-
Appearance Solid
-
Molecular Weight 353.41
-
Formula C15H15NO5S2
-
Color White to light yellow
-
SMILES
O=C(OCC)COC1=CC=C(/C=C(SC(N2)=S)\C2=O)C=C1OC
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
J Nanobiotechnology
Matrix micro/nano-topography drives oncogenic signaling and drug response in a 3D osteosarcoma model. [Abstract]2026 Mar 6;24(1):345. PMID: 41787498 -
Int J Biol Sci
The NOTCH1-HEY1 pathway regulates self-renewal and epithelial-mesenchymal transition of salivary adenoid cystic carcinoma cells. [Abstract]2020 Jan 1;16(4):598-610. PMID: 32025208
IMR-1 purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2020 Jan 1;16(4):598-610. [Abstract]
After treated with IMR-1, the cell proliferation was measured by CCK8 (D, P<0.001 by one-way ANOVA followed by Tukey’s multiple Comparison test from days 2, 3, 4 and 5) and colony formation assays (E, P<0.001 by one-way ANOVA followed by Tukey’s multiple Comparison test, n=3).
-
Oncogene
Notch signaling regulates a metabolic switch through inhibiting PGC-1α and mitochondrial biogenesis in dedifferentiated liposarcoma. [Abstract]2023 Aug;42(34):2521-2535. PMID: 37433985 -
Cell Chem Biol
Lenalidomide bypasses CD28 co-stimulation to reinstate PD-1 immunotherapy by activating Notch signaling. [Abstract]2022 Aug 18;29(8):1260-1272.e8. PMID: 35732177 -
JCI Insight
Increased CHCHD2 expression promotes liver fibrosis in nonalcoholic steatohepatitis via Notch/osteopontin signaling. [Abstract]2022 Dec 8;7(23):e162402. PMID: 36477358 -
Tissue Cell
Inhibition of ATP1V6G3 prompts hepatic stellate cell senescence with reducing ECM by activating Notch1 pathway to alleviate hepatic fibrosis. [Abstract]2024 Dec:91:102554. PMID: 39316936
Solvent & Solubility
DMSO : ≥ 100 mg/mL (282.96 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.07 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (7.07 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (272 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.8296 mL | 14.1479 mL | 28.2957 mL | 70.7394 mL |
| 5 mM | 0.5659 mL | 2.8296 mL | 5.6591 mL | 14.1479 mL | |
| 10 mM | 0.2830 mL | 1.4148 mL | 2.8296 mL | 7.0739 mL | |
| 15 mM | 0.1886 mL | 0.9432 mL | 1.8864 mL | 4.7160 mL | |
| 20 mM | 0.1415 mL | 0.7074 mL | 1.4148 mL | 3.5370 mL | |
| 25 mM | 0.1132 mL | 0.5659 mL | 1.1318 mL | 2.8296 mL | |
| 30 mM | 0.0943 mL | 0.4716 mL | 0.9432 mL | 2.3580 mL | |
| 40 mM | 0.0707 mL | 0.3537 mL | 0.7074 mL | 1.7685 mL | |
| 50 mM | 0.0566 mL | 0.2830 mL | 0.5659 mL | 1.4148 mL | |
| 60 mM | 0.0472 mL | 0.2358 mL | 0.4716 mL | 1.1790 mL | |
| 80 mM | 0.0354 mL | 0.1768 mL | 0.3537 mL | 0.8842 mL | |
| 100 mM | 0.0283 mL | 0.1415 mL | 0.2830 mL | 0.7074 mL |
Powered by Bioz